BioCentury
ARTICLE | Clinical News

Invega paliperidone ER: Phase IIIb data

November 23, 2009 8:00 AM UTC

Invega also resulted in significantly less weight gain vs. Zyprexa (p<0.0001). Serious treatment-emergent adverse events were reported in 5.7% of patients receiving Invega and in 7.3% of patients rece...